MedTech Atlas
Back to medical device regulatory guideAll countries
Middle East & AfricaENPublic regulatory overview

United Arab Emirates (UAE)

Market Overview Population: Approximately 10 million (2024); approximately 90% are expatriate residents, with UAE nationals accounting for approximately 10%; the population is high...

Updated: 2026-05-04

You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.

Sign in / register for full country report
Reference approval strategy

FDA / CE / MDSAP / NMPA benefits for this market

These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.

US FDA

510(k) / De Novo / PMAStrong benefit

FDA evidence can materially improve review confidence and may support verification, abridged, or reliance-style pathways.

Likely benefit
  • Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
  • May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
  • Does not remove local holder, language, labeling, fee, import, or post-market obligations.
View topic

EU CE

MDR / IVDRStrong benefit

CE documentation is highly reusable and may support reference, reliance, or overseas conformity assessment routes.

Likely benefit
  • Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
  • Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
  • Does not replace local registration or local representative responsibilities outside the CE-recognized route.
View topic

MDSAP

Single QMS auditIndirect QMS signal

MDSAP mainly supports ISO 13485/QMS maturity and does not reduce product review directly.

Likely benefit
  • Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
  • Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
  • Does not authorize product sale and does not replace safety, performance, or clinical evidence.
View topic

China NMPA

China registration / filingPartial / emerging acceptance

NMPA is an emerging reference factor here: it may be accepted or considered for selected products, documents, or review discussions, but the scope must be verified before filing.

Likely benefit
  • Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
  • Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
  • Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
View topic

AI Citation Summary

  • Country: United Arab Emirates (UAE)
  • Product line: Medical devices
  • Regulator / source: Regulatory Authorities — Three Parallel Systems (Core Understanding)
  • Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
  • Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
  • Key fees: Market Size: Medical device market valued at approximately USD 3 billion in 2023 — the second-largest market in the GCC after Saudi Arabia; a high-income market with per capita healthcare expenditure among the highest globally
  • Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
  • Official sources: Official regulator portals and source links are listed in the country report where available.
  • Last verified: 2026-05-04
  • Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
  • Preferred citation: MedTech Atlas

Market Overview

  • Population: Approximately 10 million (2024); approximately 90% are expatriate residents, with UAE nationals accounting for approximately 10%; the population is highly concentrated in Dubai and Abu Dhabi
  • Healthcare System: A dual-track system — a government-led public healthcare system (MOH public hospitals, Abu Dhabi's SEHA hospital network, Dubai's DHA hospital network) operating alongside a thriving private healthcare sector; private hospitals account for approximately 45% of the market, the highest proportion of private healthcare among the GCC countries
  • Market Size: Medical device market valued at approximately USD 3 billion in 2023 — the second-largest market in the GCC after Saudi Arabia; a high-income market with per capita healthcare expenditure among the highest globally
  • Market Characteristics: A population dominated by expatriates (from 180+ countries) drives high acceptance of internationally standardized medical devices; medical tourism is flourishing — Dubai Healthcare City (DHCC) is the most important medical tourism and healthcare business hub in the Middle East; multiple free trade zones (Dubai Healthcare City, JAFZA, etc.) attract international medical device companies to establish regional headquarters and distribution bases
  • Procurement Characteristics: High acceptance of premium and innovative medical devices; private hospital procurement decisions are relatively flexible; public hospital procurement is affected by government budget cycles; international brand certifications (CE/FDA) are important technical scoring criteria in procurement evaluations
  • Strategic Position: The UAE (especially Dubai) is the commercial hub for the entire Middle East and Africa (MENA/MEA) region; many multinational medical device companies establish their Middle East regional headquarters in Dubai, serving Saudi Arabia, Qatar, Kuwait, Egypt, Africa, and surrounding markets

Regulatory Authorities — Three Parallel Systems (Core Understanding)

The UAE is a federal state, and medical device regulation has a distinctive federal-and-emirate parallel structure. To access the full UAE market, manufacturers typically face three relatively independent registration systems:

System 1: MOHAP (Federal Level)

  • Full Name: Ministry of Health and Prevention
  • Jurisdiction: Federal level, covering the five smaller emirates outside Dubai and Abu Dhabi (Sharjah, Ajman, Umm Al Quwain, Fujairah, Ras Al Khaimah); additionally, a MOHAP registration certificate carries basic validity nationwide
  • Online System: MOHAP eServices (https://mohap.gov.ae)
  • Key Regulations: Federal Law No. 4 of 1983 (on pharmaceuticals and medical devices) and subsequent amendments; MOHAP Medical Devices Regulation

System 2: DHA (Dubai Emirate Level)

  • Full Name: Dubai Health Authority
  • Jurisdiction: The Emirate of Dubai (including all Dubai healthcare institutions: Dubai Healthcare City, Jumeirah, Deira, etc.)
  • Online System: DHA Sheryan System (https://sheryan.dha.gov.ae)
  • Key Characteristics: Dubai is the UAE's largest private healthcare market; DHA registration is a prerequisite for entering the Dubai healthcare market; healthcare institutions within Dubai Healthcare City (DHCC) must comply with DHA regulations

System 3: DOH (Abu Dhabi Emirate Level)

  • Full Name: Department of Health Abu Dhabi (formerly HAAD)
  • Jurisdiction: The Emirate of Abu Dhabi (including Abu Dhabi city, Al Ain, Al Dhafra, and other Abu Dhabi areas)
  • Online System: DOH ShafaMIS System (https://www.doh.gov.ae)
  • Key Characteristics: Abu Dhabi is the UAE's political capital with the largest public healthcare system (SEHA hospital network); DOH has significant influence over procurement of high-end specialist equipment

Practical Guidance

Covering the full UAE market typically requires: MOHAP + DHA + DOH — three separate registrations, or selective registration based on the target sales region (e.g., for Dubai market only, prioritize DHA; for the five smaller emirates only, MOHAP is sufficient). The three systems have highly similar registration requirements but differ in details, and documents must be adapted for each.

Device Classification System

Local Class Risk Level EU Equivalent FDA Equivalent Description
Class A Lowest risk Class I Class I Non-invasive, low-contact devices; simple single-use consumables
Class B Low-medium risk Class IIa Class II (partial) Short-term invasive devices, routine diagnostic equipment, surgical instruments, etc.
Class C Medium-high risk Class IIb Class II–III Long-term non-cardiovascular implants, high-energy therapy devices
Class D Highest risk Class III Class III/PMA Cardiovascular implants, neural devices, devices incorporating animal-derived materials

Note: The classification rules of all three systems (MOHAP, DHA, DOH) are essentially consistent, all referencing the international GHTF/IMDRF classification framework. Product classification must be confirmed with the target registration authority before the registration application; the three systems may have subtle differences in classification determinations for borderline products.

Registration Pathways

During the limited-time free period, sign in or register to view the complete medical device country report.